Quality & complianceOfficial

Denmark flags supply problems for Paranova's parallel-imported Zyprexa 10 mg injection

🇩🇰 DKMA · Mon 26 Oct 2026

The Danish Medicines Agency reports delivery difficulties with olanzapine powder for solution for injection from Paranova Danmark ApS, with no end date given.

The Danish Medicines Agency (DKMA) has published a supply notice for Zyprexa 10 mg powder for solution for injection supplied by Paranova Danmark ApS. The notice is dated 26 October 2026 and refers to current problems with supply.

The product contains the active substance olanzapine (ATC code N05AH03). DKMA gives the expected period of the problem as mid-October 2026 to unknown, so the notice does not say when supply might normalise.

The stated cause is delivery difficulties. The notice does not explain these further. It also does not name alternative products or set out any measures for managing the shortage.

DKMA tells readers to direct questions about the current status to the company. The notice sits in the agency's list of announcements on medicine supply. Paranova is a parallel importer, meaning the product is sourced from another European market for sale in Denmark.

What it means for your team

  • Supply and procurement teams in Denmark should check current availability of Paranova's Zyprexa 10 mg injection directly with the company, as DKMA advises.
  • The notice names no end date and no alternatives, so contingency planning cannot rely on it for timing or substitutes.
  • Teams tracking shortages of olanzapine injectables may want to log this as an open-ended parallel-import supply issue that began in mid-October 2026.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →